talimogene laherparepvec (Imlygic)
Jump to navigation
Jump to search
Indications
- unresectable cutaneous melanoma[1]
Contraindications
Dosage
Adverse effects
Mechanism of action
- genetically modified live herpes simplex virus type 1 (HSV1)
- does improve overall survival or benefit patients metastatic melanoma
Notes
- expected cost: $65,000[1]
More general terms
References
- ↑ 1.0 1.1 1.2 FDA News Release. October 27, 2015 FDA approves first-of-its-kind product for the treatment of melanoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm469571.htm
Amgen News Release. October 27, 2015 FDA Approves IMLYGIC<TM> (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US. https://www.amgen.com/media/news-releases/2015/10/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us/ - ↑ 2.0 2.1 Fuerst ML Gregory Goldmacher, MD, PhD, MBA, on New Response Criteria for Intratumoral Immunotherapy - New response criteria developed for intratumoral immunotherapy clinical trials MedPage Today. ASCO Reading Room 08.06.2020 https://www.medpagetoday.com/reading-room/asco/immunotherapy/87918